Today: 8 February 2026
Subscribe
Browse Category

NYSE:HIMS News 3 November 2025 - 7 February 2026

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
7 February 2026
··
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
7 February 2026
····
Hims & Hers (HIMS) stock slips again as $49 Wegovy copy draws FDA heat and Novo legal threat

Hims & Hers (HIMS) stock slips again as $49 Wegovy copy draws FDA heat and Novo legal threat

Hims & Hers Health shares fell 2.6% to $22.88 Friday after launching a $49 compounded version of Novo Nordisk’s Wegovy weight-loss pill. Novo called the move “illegal mass compounding” and threatened legal action, while the FDA warned it would act against unapproved copycat drugs. Hims said its pill uses “liposomal technology” to aid absorption but gave no details. Nearly a third of Hims shares are out on loan for short bets.
6 February 2026
·
Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly shares rose 3% Friday after the FDA chief warned of a crackdown on non-approved copycat weight-loss drugs. The rebound followed an 8% drop Thursday, triggered by news of a $49 compounded rival to Novo Nordisk’s Wegovy. Investors are watching Lilly’s 2026 outlook and the FDA’s April decision on its oral obesity drug. Fourth-quarter revenue jumped 43% to $19.3 billion, led by strong sales of Mounjaro and Zepbound.
6 February 2026
····
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers Health shares fell 0.5% to $32.87 in premarket trading Wednesday after closing down 3.1% the previous session. The move follows price cuts by Novo Nordisk and Eli Lilly on obesity drugs in China, raising questions about future margins and demand for GLP-1 therapies. Hims recently launched its weight-loss membership in the UK, offering access to Wegovy and Mounjaro.
31 December 2025
····
Hims Stock (HIMS) Outlook for 2026: Latest News, Canada Expansion, Buyback and Price Targets as of December 6, 2025

Hims Stock (HIMS) Outlook for 2026: Latest News, Canada Expansion, Buyback and Price Targets as of December 6, 2025

Hims & Hers Health (NYSE: HIMS) is back in the spotlight after a new $250 million buyback, expansion into Canada, and fresh acquisitions in lab testing and blood diagnostics. Here’s a comprehensive look at HIMS stock price, latest news, GLP‑1 risks, and Wall Street forecasts as of December 6, 2025. Hims Stock Today: Price, Valuation and Volatility As of the close on Friday, December 5, 2025, Hims & Hers Health (NYSE: HIMS) finished trading at around $39–39.3 per share, giving the telehealth company a market capitalization of roughly $8.9–9.0 billion. MarketBeat+2CoinCodex+2 Over the last 12 months, HIMS has traded between
6 December 2025
·
Hims & Hers (HIMS) Stock Jumps on Canada Launch and YourBio Deal: Latest News, Forecasts and Analysis for December 4, 2025

Hims & Hers (HIMS) Stock Jumps on Canada Launch and YourBio Deal: Latest News, Forecasts and Analysis for December 4, 2025

Hims & Hers Health, Inc. (NYSE: HIMS) is back in the spotlight. In Thursday’s session on December 4, 2025, the telehealth stock climbed roughly 5–8%, trading around $40 and valuing the company at about $12.8 billion, after a flurry of strategic announcements. Finviz+1 The immediate catalysts: At the same time, fresh coverage from MarketBeat, TipRanks, Zacks and others is revisiting the stock’s valuation, short interest and earnings trajectory. MarketBeat+3MarketBeat+3TipRanks+3 Below is a detailed, news‑driven look at HIMS stock as of December 4, 2025 – including today’s headlines, the latest financials, analyst forecasts, and the key bull and bear arguments. HIMS
4 December 2025
···
Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

Hims & Hers (HIMS) Stock Soars on Subscriber Surge and GLP-1 Deal Buzz – Nov 2025 Update

Current Stock Price (Nov 3, 2025) Hims & Hers Health’s stock (NYSE: HIMS) closed on Nov 3, 2025 at $44.39, down about 2.3% for the daystockanalysis.com. This modest dip came amid a broader mixed market and ahead of the company’s earnings release after the bell. However, immediately following its Q3 earnings report that evening, HIMS shares jumped roughly 6% in after-hours trading, climbing to around $46.70investing.com. The post-market pop was driven by upbeat revenue and subscriber numbers (more on that below), signaling renewed investor optimism. Even after recent volatility, HIMS stock has had a stellar year. At ~$44–$47, shares remain
4 November 2025
·
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Analyst outlook & forecast: Long-term, analysts model robust growth. For example, one financial model projects ~18% revenue CAGR: ~$3.3 billion in sales by 2028 and ~$261 million net incomesimplywall.st. Another estimate sees revenue rising from ~$2.35 B in 2025 to ~$3.34 B by 2027tipranks.com, and free cash flow turning positive in 2025simplywall.st. These forecasts assume continued momentum in weight-loss/metabolic services plus gains in new verticals. Yet many investors note the high valuation (HIMS trades near ~$45 with market cap in the billions) and regulatory/legal risks. Community “fair value” estimates vary widely (some as low as $41) due to uncertaintysimplywall.st. Key analysts (TD Cowen, KeyBanc) maintain
3 November 2025
···

Stock Market Today

KLA stock price jumps 8% as chip rebound lifts KLAC — what to know before Monday

KLA stock price jumps 8% as chip rebound lifts KLAC — what to know before Monday

8 February 2026
KLA Corp shares surged 8.4% to $1,442.95 Friday, leading gains in chip-equipment stocks after Amazon announced a major increase in capital spending. About 1.6 million KLA shares traded as the PHLX semiconductor index rose 5.7%. KLA’s board declared a $1.90 quarterly dividend, payable March 3 to holders as of Feb. 17. Applied Materials and Lam Research also rallied sharply into the close.
CBA share price: Commonwealth Bank stock steadies after ASX selloff as earnings loom

CBA share price: Commonwealth Bank stock steadies after ASX selloff as earnings loom

8 February 2026
Commonwealth Bank of Australia closed Friday down 0.23% at A$158.91, outperforming a 2.03% drop in the S&P/ASX 200. Investors await CBA’s half-year results on Feb. 11 and commentary from CEO Matt Comyn. The Reserve Bank’s recent cash-rate hike to 3.85% and upcoming mortgage repricing are in focus. CBA flagged A$68 million in provisions and A$53 million in non-recurring income items.
Boeing stock jumps 2.6% to $243 — what Wall Street is watching before Monday

Boeing stock jumps 2.6% to $243 — what Wall Street is watching before Monday

8 February 2026
Boeing shares closed up 2.6% at $243.03 Friday, buoyed by reports of possible major aircraft orders from Saudi Arabia and India. India’s trade minister said a $70–80 billion Boeing deal could be signed by March. Supply-chain delays and regulatory scrutiny remain key risks. Boeing’s chief engineer sold over 10,000 shares earlier in the week.
Go toTop